Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
-
Barcelona reinstate Ter Stegen as captain
-
Fleetwood leads St. Jude in search of first US PGA Tour title
-
Gold futures hit record on US tariff shock; mixed day for stocks
-
Trump says Armenia, Azerbaijan committed to end fighting 'forever'
-
England's injured Woakes still has Ashes hopes
-
US astronaut Jim Lovell, Apollo 13 commander, dead at 97
-
Swiss gold refining sector stung by US tariffs
-
New Instagram location sharing feature sparks privacy fears
-
Spain's Badosa withdraws from US Open
-
Mexico seeks compensation from Adidas in cultural appropriation row
-
NBA Celtics sign Mazzulla to coaching contract extension
-
Swiss gold refining sector hits US tariff mine
-
Ter Stegen responds after Barcelona strips him of captaincy
-
Chelsea's Broja joins Burnley on five-year deal
-
Three centurions as 'ruthless' New Zealand pile on runs against Zimbabwe
-
Three die in Greece as gales stoke fires, disrupt ferries
-
ICC unseals Libya war crimes warrant for militia officer
-
Montreal protagonists Mboko, Osaka out of Cincinnati Open
-
Trump says court halt of tariffs would cause 'Great Depression'
-
Glasner says demotion to Conference League would punish 'innocent' Palace
-
New Zealand build big total in 2nd Test against Zimbabwe
-
Trump hosts foes Armenia, Azerbaijan in his latest peace initiative
-
Nigerian scientists await return of Egusi seeds sent to space
-
Pioneer spirit drives Swiss solar-powered plane altitude attempt
-
Thyssenkrupp to spin off marine division amid defence boom
-
Vance and Lammy talk Gaza, fish as US VP starts UK holiday
-
Israel plans to 'take control' of Gaza City, sparking wave of criticism
-
Putin taps key allies ahead of Trump summit, sanctions deadline
-
Two tourists die, fires erupt in Greece amid gale-force winds
-
Lens sign France international Thauvin from Udinese
-
Gold futures hit record on US tariff shock, stocks wobble
-
Man Utd training ground upgrade will foster 'winning culture': Ratcliffe
-
Two tourists die at sea in Greece amid gale-force winds
-
'Optimistic': Champagne growers hope for US tariff shift
-
French firefighters optimistic after controlling vast wildfire
-
Germany suspends arms exports to Israel for use in Gaza
-
Stocks waver, gold futures hit record on US tariff updates
-
Guessand says he jumped at chance to join Aston Villa after sealing move
-
Israel to 'take control' of Gaza City, sparking wave of criticism
-
Accumulating bitcoin a risky digital rush by companies?
-
Liverpool's Slot hints at fresh Isak bid despite 'attacking power'
-
PSG to sign Lille goalkeeper Lucas Chevalier: source
-
Oil industry presence surges at UN plastic talks: NGOs
-
Kipyegon says a woman will run a sub-four minute mile
-
Tokyo soars on trade deal relief as most Asian markets limp into weekend
-
Israel to 'take control' of Gaza City after approving new war plan
-
Australian A-League side Western United stripped of licence
-
'Back home': family who fled front buried after Kyiv strike
-
Indonesia cracks down on pirate protest flag
-
Israeli army will 'take control' of Gaza City: PM's office
NYSE - LSE
| RBGPF | -5.79% | 71.84 | $ | |
| RYCEF | -0.7% | 14.35 | $ | |
| VOD | 0.88% | 11.36 | $ | |
| NGG | -1.51% | 71.01 | $ | |
| CMSC | 0.39% | 23.05 | $ | |
| RELX | -2.2% | 48 | $ | |
| RIO | 1.76% | 61.86 | $ | |
| GSK | 0.58% | 37.8 | $ | |
| BTI | 0.96% | 57.24 | $ | |
| CMSD | 0.25% | 23.58 | $ | |
| SCU | 0% | 12.72 | $ | |
| SCS | -0.76% | 15.88 | $ | |
| BCC | -1.34% | 82.09 | $ | |
| JRI | 0.19% | 13.435 | $ | |
| BCE | 2.34% | 24.35 | $ | |
| AZN | -0.69% | 73.55 | $ | |
| BP | -0.15% | 34.14 | $ |
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today that the U.S. District Court for the District of Massachusetts has ruled in favor of Radius and co-plaintiff Ipsen Pharma S.A.S. ("Ipsen") in a patent infringement suit against Orbicular Pharmaceutical Technologies Private Ltd. ("Orbicular") for their proposed generic for TYMLOS® (abaloparatide) for osteoporosis. Radius and Ipsen prevailed, and the court upheld the validity of all five TYMLOS® patents asserted, in which the latest to expire will remain in effect through April 30, 2038.
The suit was brought by Radius and Ipsen in September 2022 alleging patent infringement by Orbicular in their attempt to seek FDA approval to market a generic abaloparatide product. Radius asserted that Orbicular's proposed generic product would infringe five patents held by Radius.
The favorable ruling reinforces the strength of the TYMLOS® patent portfolio and represents an important win for Radius.
About Radius:
Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, a parathyroid hormone related peptide, is approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women and men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. Abaloparatide is supplied as a single-patient multi-use prefilled pen designed to subcutaneously administer 80 micrograms per dose over a 30-day period. For additional information, please visit www.TYMLOS.com.
Contact:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: [email protected]
SOURCE: Radius Health
View the original press release on ACCESS Newswire
P.Martin--AMWN